Oncoinvent CEO, Jan A. Alfheim will present the company at the DnB Nordic Healthcare Conference 2019 at the venture session for scaleups.
Menu
Onc File published (year): 2019
Oncoinvent CEO, Jan A. Alfheim will present the company at the Nordic American Life Science Conference in New York, USA
Press Release 05.2019: Oncoinvent announced today that research relating to a radioactivity standard for radium-224 (224Ra) in secular equilibrium has been published in the Journal of Applied Radiation and Isotopes by Oncoinvent research scientist Elisa Napoli and researchers from the National Institute of Standards and Technology (NIST). This is an important step in the development of Radspherin® as the standard will form the basis for calibration of clinical doses of Radspherin®.
Oncoinvent would like to extend an invitation to a presentation of the Q3 2019 results. The presentation will be held at 14:00 on Thursday 31. October 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor. To attend, please register with kvam@oncoinvent.com The quarterly report will be made available on www.oncoinvent.com on the 31. … Read more
CSO Tina Bønsdorff, presented the ePoster «Feasibility of Ra-224 SPECT CT imaging in a therapeutic setting – a phantom study» developed by Stokke (PhD, Assoc. Prof) and Mikalsen (PhD) at Oslo University Hospital, Oslo, NORWAY, at the European Association of Nuclear Medicine (EANM) annual conference held in Barcelona.
Oncoinvent would like to extend an invitation to a presentation of the Q2 2019 results. The presentation will be held at 15:00 on Thursday 29. August 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor. Going forward quarterly result presentations will be held on a regular basis. To attend, please register with kvam@oncoinvent.com … Read more
Oncoinvent researcher Elisa Napoli will present the poster “A primary activity standard for the alpha-emitting radionuclide Ra-224” at the SNMMI 2019 Annual Meeting.
Jan A. Alfheim, CEO of Oncoinvent will give a short status presentation about the company at the ABG Sundal Collier’s Norwegian Biotech Oncology Seminar
Oncoinvent CEO Jan A. Alfheim will be presenting the company during the International Cancer Cluster Showcase at the BIO International Convention 2019.
Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.
